News | November 14, 2024
AbbVie provides update on Phase 2 results for Emraclidine in schizophrenia
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Granules now has a total of 67 ANDA approvals from the USFDA
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
Prednisolone Acetate Ophthalmic Suspension is the first generic version of Pred Forte
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Subscribe To Our Newsletter & Stay Updated
